Phase 3Completed
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)
A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease
- Sponsor
- Eli Lilly and Company (Industry)
- Enrolment
- 1,946 enrolled
- Conditions
- Obesity; Cardiovascular Diseases
- Interventions
- Retatrutide; Placebo
- Ages
- adults, older adults
- Registry
- NCT05882045, CTIS2023-503659-88-00
Full record on ClinicalTrials.gov
From the registry
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Primary outcomes
- Percent Change from Baseline in Body Weight
History
Last registry update
Study completion
Primary completion
Registered
Started
In the news
TrialsThe Lancet (opens The Lancet in a new tab)
Phase 3 trial links retatrutide to weight loss and glycemic control
The phase 3 TRIUMPH-2 trial showed retatrutide substantially lowered bodyweight and improved glycaemic control in patients who have obesity alongside type 2 diabetes.
ResearchNEJM (opens NEJM in a new tab)
NEJM publishes study on retatrutide for the treatment of obesity
The journal reports findings on retatrutide, an agonist targeting three hormone receptors, as a potential therapy for people with obesity.
